April 27-29, 2021 | Digital Event
www.mitochondria-targets.com
9AM - 5PM EST | 3PM - 11AM CEST

BOOK BY FEBRUARY 12 & SAVE UP TO $750

WELCOME
SPEAKERS
AGENDA
PARTNER WITH US
REGISTER YOUR PLACE

DIGITAL
Mitochondria-Targeted Drug Development

Understand Mitochondrial Dysfunction & Enhance Mitochondria-Targeted Research whilst Advancing Therapeutics for Mitochondrial & Age-related Diseases

Expert Speakers Include:

Reenie McCarthy
Chief Executive Officer
Stealth BioTherapeutics

Paul Thompson
Chief Scientific Officer
MISSION Therapeutics

Magali Taiel
Chief Medical Officer
GenSight Biologics

Steven Engle
Chief Executive Officer
CohBar

John Geisler
Founder & Chief Scientific Officer
Mitochon Pharmaceuticals

"The quality of the attendees and the speakers was outstanding. The speakers were exceptional I was blown away. I'm still trying to recover"
Chief Executive Officer & Chief Financial Officer, Bach Pharma

(+1) 617 455 4188 info@hansonwade.com
www.mitochondria-targets.com

hansonwade

Welcome to the digital Mitochondria-Targeted Drug Development Summit!

Mitochondria-Targeted Drug Development

April 27-29th 2021 | Digital
9AM - 5PM EST | 3PM - 11PM CEST

Understand Mitochondrial Dysfunction & Enhance Mitochondria-Targeted Research whilst Advancing Therapeutics for Mitochondrial & Age-related Diseases

Participate in this definitive meeting focusing on the latest research in innovative targeting pathways, unique therapeutics and new techniques to target mitochondrial dysfunction, whilst evaluating your clinical development landscape.

Join 80+ of the leading experts in targeting mitochondria, including Stealth **BioTherapeutics Cohbar, GenSight Biologics, Minovia Therapeutics** and **MISSION Therapeutics** as they drive towards better understanding how to create effective and scalable mitochondrial therapies. Including sessions about optimizing and improving the persistence and durability of these therapies for chronic acquired age-related and rare genetic mitochondrial diseases, it's a conversation not to miss.

Incorporating insights from leading academics and pioneering biotech, this meeting will uncover innovative research whilst helping you gain extensive technical knowledge on mitochondria-targeted therapies. Get all the necessary tools to succeed, from exploring how to overcome challenges with evaluating compounds, gaining approval in various diseases affected by mitochondria dysfunction to understanding difficulties with biomarkers of mitochondria, and levels of mitochondria per cell.

What previous attendees have said about Hanson Wade meetings:

"The expertise of the speakers and range of topics was impressive for a small meeting. The size of the meeting facilitated extensive discussions among the speakers and participants"

Director, Toxicology, Biogen

"The meeting provided a great opportunity for discussion, feedback, and networking alongside an all-star speaker line up"

Senior Associate Director, The Michael J. Fox Foundation for Parkinson's Research

Your Checklist to Advancing Mitochondria Targeted Therapies

Mitokinin showcase how to activate PINK1 dependent mitochondrial quality control to treat Parkinson's Disease

MITOKININ

Larimar Therapeutics examine CTI-1601 as a potential protein replacement therapy under development for Friedreich's Ataxia

Larimar Therapeutics

Explore with **Mitochon Pharma** meaningful pleiotropic pharmacology for truly insidious pleiotropic diseases

Mitochon Pharmaceuticals

Discuss with **Petrotope** preclinical and early clinical evidence of stabilized Polyunsaturated Fatty Acid as drug therapy in diseases of mitochondrial deficiency

RETROTOPE

Evaluate with **PTC Therapeutics** lessons learned in the development of therapies for mitochondrial disease & how to progress the industry forward

PTC THERAPEUTICS

(+1) 617 455 4188 info@hansonwade.com
www.mitochondria-targets.com

hansonwade

Meet your 25+ Expert Speakers

Steven Engle
Chief Executive Officer
CohBar Inc

Magali Taiel
Chief Medical Officer
GenSight Biologics

Carole Ben-Maimon
President & Chief Executive Officer
Larimar Therapeutics

Mehmood Khan
Chief Executive Officer
Life Biosciences

Natalie Ohana Yivgi
Co-Founder & Chief Executive Officer
Minovia Therapeutics

Paul Thompson
Chief Scientific Officer
MISSION Therapeutics

John Geisler
Founder & Chief Scientific Officer
Mitochon Pharmaceuticals

Nicholas Hertz
Chief Scientific Officer
Mitokinin

Francesca Fieni
Founder & Chief Scientific Officer
Pano Therapeutics

Sophie Bozec
Senior Vice President, R&D Pharmacology & Co-founder
POXEL

Matthew Klein
Chief Development Officer
PTC Therapeutics

Robert Molinari
Chief Executive Officer
Retrotope

Reenie McCarthy
Chief Executive Officer
Stealth BioTherapeutics

Nathan Alder
Associate Professor
University of Connecticut

Philip Yeske
Science & Alliance Officer
United Mitochondrial Disease Foundation

Lan Wei-LaPierre
Professor
University of Florida

Mike Murphy
Principal Investigator, MRC Mitochondrial Biology Unit
University of Cambridge

Keshav Singh
Joy & Bill Harbert Endowed Chair & Professor
University of Alabama
Scientific Founder & Chief Scientific Officer
Yuva Biosciences

Jake Chen
Professor of Biomedical Engineering
University of Alabama at Birmingham

Gyaneshwer Chaubey
Professor of Zoology (Molecular Anthropology)
BHU

Prashanth Suravajhala
Senior Scientist, Department of Biotechnology & Bioinformatics
Birla Institute of Scientific Research



Afshin Beheshti
Bioinformatician & Principal Investigator
KBR/NASA



Douglas Wallace
Michael & Charles Barnett Endowed Chair, **Pediatric Mitochondrial Medicine & Metabolic Disease**, Director, **Center for Mitochondrial & Epigenomic Medicine**, Professor, **University of Pennsylvania**



Daniela Bezdan
Research Associate
University Hospital Tuebingen
Co-Chair
NASA GeneLab Microbiome
Co-Chair
ISSOP



Sylvain Costes
GeneLab Project Manager & Principal Investigator, Acting Branch Chief of Space Biosciences Research Branch
NASA Ames Research Center



Deanne Taylor
Director of bioinformatics, Department of Biomedical & Health Informatics
The Children's Hospital of Philadelphia



Kapaett Satyamoorthy
Professor & Director
Manipal School of Life Sciences, MAHE

Kira Mann
Chief Executive Officer
MitoAction

"Many scientific viewpoints are openly shared"
Professor, Bioengineering, UC Berkeley

Pre-Conference Focus Day
Tuesday April 27, 2021

10AM - 4PM EST | 5PM - 10PM CEST

Workshop A | **10.00AM-12.30PM EST | 5.00PM-6.30PM CEST**

Decoding SARS-CoV-2 Hijacking of Host Mitochondria in COVID-19 Pathogenesis

SARS-CoV-2 harbors a lot of known unknown regions in the form of hypothetical open reading frames [ORFs] and the mechanisms underlying the disease pathogenesis is not clearly understood. We observe that distinct localization of viral RNA and proteins in mitochondria play essential roles in SARS-CoV-2 pathogenesis, and understanding the mechanisms underlying virus communication with host mitochondria is important. On the other hand, long noncoding RNAs [lncRNAs] are known to play a key regulatory role in the viral pathogenesis from endocytosis. We derived a hypothesis and asked whether the lncRNAs in the host are candidly associated with the viral proteins or any other host proteins which we believe are "trespassed" regulating SARS-CoV-2 pathogenesis.

The workshop covers the following talks and session in a nutshell:

- Comprehensive Review of Coronavirus Regulation of Mitochondrial Structure & Function & Actual Data Presentation Describing Recent Publication - *Kapaett Satyamoorthy & Keshav Singh*
- Identify the Known & Unknowns from SARS-CoV-2: Challenges & Implications on Annotation (Long Non-coding RNA) - *Prashanth Suravajhala*
- A Deep Dive into PAGER SARS-CoV- 2 Databases - *Jake Chen*
- Mitochondrial Phylogenetics of World, the SARSCoV-2 Pathogenesis & ACE2 relevance in COVID-19 - *Gyaneshwer Chaubey*
- Panel Discussion - *Keshav Singh, Prashanth Suravajhala, Jake Chen, Gyaneshwer Chaubey & Kapaett Satyamoorthy*

Workshop Leaders

Jake Chen
Professor of Biomedical Engineering
University of Alabama

Gyaneshwer Chaubey
Professor of Zoology (Molecular Anthropology)
Banaras Hindu University

Prashanth Suravajhala
Senior Scientist, Department of Biotechnology & Bioinformatics
Birla Institute of Scientific Research

Keshav Singh
Joy & Bill Harbert Endowed Chair & Professor
University of Alabama
Scientific Founder & Chief Scientific Officer
Yuva Biosciences

Kapaett Satyamoorthy
Professor & Director
Manipal School of Life Sciences, MAHE

"Several presentations and discussions with upcoming talents in the life sciences"

Chief Scientific Officer, TeneoBio

Pre-Conference Focus Day
Tuesday April 27, 2021

10AM - 4PM EST | 5PM - 10PM CEST

Workshop B | **1.30PM-4.00PM EST | 7.30PM-10PM CEST**

Mitochondrial Changes Key to Health Problems in Space

Systems Biology Approach Reveals Mitochondrial to be Driving Health Risks Associated with Spaceflight

- Multi-omics approach utilized to examine universal key biological changes that occur during spaceflight
- Analysis revealed mitochondria being potential systemic master regulator causing key downstream changes due to spaceflight that contribute to increased health risks.
- Multiple pathways regulated by mitochondrial during spaceflight is also impacted which include: circadian rhythm, immune suppression, lipid accumulation, fatty acid metabolism, and olfactory pathways.
- Astronaut physiological and NASA Twin Study data utilized to confirm results. - *Afshin Beheshti*

Cell-free mitochondrial DNA (cf-mt-DNA), cell-free DNA & Exosome Profiling from a Year-Long Human Spaceflight Reveals Circulating Biomarkers

- Learn how liquid biopsy can monitor the health conditions of astronauts during spaceflight
- Examine increases in cell-free mitochondrial DNA and how they were found during spaceflight
- Discover how post-flight astronaut blood had exosome increases and brain-derived peptides
- Study how controls for sampling from the ISS can correct for technical noise - *Daniela Bezdan*

Panel Discussion - *Sylvain Costes, Deanne Taylor & Afshin Beheshti*

Workshop Leaders

Daniela Bezdan
Research Associate
University Hospital Tuebingen
Co-Chair
NASA GeneLab Microbiome
Co-Chair
ISSOP

Sylvain Costes
GeneLab Project Manager & Principal Investigator, Acting Branch Chief of Space Biosciences Research Branch
NASA Ames Research Center

Deanne Taylor
Director of bioinformatics, Department of Biomedical & Health Informatics
The Children's Hospital of Philadelphia

Afshin Beheshti
Bioinformatician & Principal Investigator
KBR/NASA

"I had access to very interesting research in a concentrated period of time."

Founder, CFO & President, SIWA Therapeutics

DAY ONE
Wednesday April 28, 2021

9AM - 5PM EST | 3PM - 11PM CEST

8.00 | 2.00 **Online Registration & Virtual Coffee Networking**

8.45 | 2.45 **Chair's Opening Remarks**

Overview of the Landscape: The Role of Mitochondrial Dysfunction in Age-related Diseases & Rare Genetic Diseases

9.00 | 3.00 **Keynote Presentation: Mitochondria; How the Relic from Biology Class Could be a Powerhouse for Biotech Innovation**

Reenie McCarthy
CEO
Stealth Biotherapeutics

- Examine the potential of mitochondrial medicine for rare genetic diseases and common diseases of aging
- Understand targeting the mitochondria: Upstream, downstream, inner, outer, matrix
- Explore the platform approach to address metabolic cardiomyopathies and ophthalmic and neurological disorders

9.30 | 3.30 **Panel Discussion: Evaluate the Current Challenges, Approaches & Opportunities in Targeting-Mitochondria for Age-related & Mitochondrial Diseases**

- How can drug developers/research cut to the real barriers, and debate what is truly required to break through to successful treatments for mitochondrial diseases?
- What's the impact of COVID-19 and its repercussions on existing clinical trials/research?

Matthew Klein
Chief Development Officer
PTC Therapeutics

Deanne Taylor
Director of bioinformatics, Department of Biomedical & Health Informatics
The Children's Hospital of Philadelphia

Natalie Ohana Yivgi
Co-Founder & Chief Executive Officer
Minovia Therapeutics

Steven Engle
Chief Executive Officer
CohBar, Inc

Nicholas Hertz
Chief Scientific Officer
Mitokinin

Early Discovery & Research: Why Target Mitochondria for Drug Development?

Keshav Singh
Joy & Bill Harbert Endowed Chair & Professor
University of Alabama
Scientific Founder & Chief Scientific Officer
Yuva Biosciences

10.15 | 4.15 **Targeting Mitochondria for Skin Rejuvenation**

- Examine how mitochondria play a vital role in the skin
- Discuss how mitochondrial dysfunction induces skin aging
- Consider how skin disorders manifest mitochondrial dysfunction
- Take a further look at how targeting mitochondria can help rejuvenate skin

10.45 | 4.45 **Virtual Speed Networking**

Grab a coffee from the comfort of your own kitchen and jump into this 1:1 networking session to make new connections, exchange virtual business cards and maybe even see a friendly face or two!

11.15 | 5.15 **Using mitochondrial Ca2+ Uptake as a Therapeutic Target for Amyotrophic Lateral Sclerosis (ALS)**

Lan Wei-LaPierre
Professor
University of Florida

- Determine the contribution of skeletal muscle in ALS pathogenesis
- Characterize the progression of ALS in a mouse model using comprehensive longitudinal studies
- Explore the therapeutic potential of inhibiting mitochondrial Ca2+ uptake in ALS mice using a newly-generated inducible genetic mouse model (Genetic intervention)
- Assess the protective effect of a mitochondrial uncoupler (indirectly inhibit mitochondrial Ca2+ uptake), MP101/MP201, in a ALS mouse model (Pharmacological intervention)

DAY ONE
Wednesday April 28, 2021

9AM - 5PM EST | 3PM - 11PM CEST

Mehmood Khan
CEO
Life Biosciences

11.45 | 5.45

Novel Mitochondrial Uncoupler Therapeutics & Beyond

- Examine new generation "smart-design" mitochondrial uncouplers
- Enable technology to treat age-related diseases
- Understand transformative therapies for metabolic diseases and tissue injury

Preclinical & Translational Development: Advancing Early Stage Development with Mitochondrial-Targets

Nicholas Hertz
Chief Scientific Officer
Mitokinin

12.15 | 6.15

Activating PINK1 Dependent Mitochondrial Quality Control to Treat Parkinson's Disease

- Examine 3/A strategy to selectively activate PINK1 by stimulating autophosphorylation
- Take a look at identification of a potent, brain penetrant, PINK1 activator, MTK458
- Evaluate how MTK458 drives clearance of synuclein pathology in in vivo Parkinson's models
- Understand how MTK458 is a valuable pharmacological tool to interrogate PINK1 biology in vivo

12.45 | 6.45

Networking Lunch

Paul Thompson
Chief Scientific Officer
MISSION Therapeutics

1.45 | 7.45

USP30 inhibitors: Releasing the Brakes to Improve Mitochondrial Quality Control During Disease

- Consider how USP30 is the only mitochondrial deubiquitylating enzyme, perfectly placed to regulate mitochondrial ubiquitin and quality control
- Examine USP30 inhibitor target engagement and how pharmacodynamics can be followed in-vivo
- Explore Multiple disease pathologies and how they are prevented/ reversed by USP30 inhibitors

Robert Molinari
Co-founder
Retrotope

2.15 | 8.15

Preclinical & Early Clinical Evidence of Stabilized Polyunsaturated Fatty Acid (PUFA) as Drug Therapy in Diseases of Mitochondrial Deficiency

- Examine how a worsening cascade of lipid peroxidation of PUFAs leads to cell dysfunction and death - often through mitochondrial loss of function
- View how reducing lipid peroxidation with the use of stabilized lipid drugs mitigates LPO-based cell death may halt or reverse progression of disease by restoring mitochondrial function
- Showcase how clinical and pre-clinical proof of concept has been established in several diseases

Francesca Fieni
Founder & Chief Scientific Officer
Pano Therapeutics

2.45 | 8.45

Mitochondrial Ion Channels as Therapeutic Targets

- Review the field of exploring and targeting mitochondrial ion channels
- Examine Pano's Novel, Non-selective Cation Channel (NMCC) in the inner mitochondrial membrane discovery and significance as target
- Explore connecting NMCC to complex diseases/disorders

3.15 | 9.15

Afternoon Break & Virtual Networking

- Grab a coffee from the comfort of your own kitchen and jump into this group networking session to make new connections om our group networking sessions!
- Visit the Live Demo Area & Virtual Exhibition Hall

DAY ONE
Wednesday April 28, 2021

9AM - 5PM EST | 3PM - 11PM CEST

The Importance of Patient Perspective when Developing Drugs for Mitochondrial Disease

3.45 | 9.45 **Utilizing Technology to Better Understand Mitochondrial Disease & the Patient Journey**

Kira Mann
Chief Executive Officer
MitoAction

- Optimize patient-centric data-driven approaches to unlocking a meaningful understanding of day-to-day and real-life experiences of the mito patient
- Enable patient centricity in a way that transforms the patient experience in being an active partner in the clinical trials experience
- Provide reliable recording of symptoms and other relevant patient-reported outcomes data to complement trial data and to support better care decisions

4.15 | 10.15 **Building the Mitochondrial Disease Patient Perspective, One Voice at a Time**

Philip Yeske
Science & Alliance Officer
United Mitochondrial Disease Foundation

- Examine why it is important to engage patient community early in the therapeutic development process
- Learn to understand burden of the disease as well as what meaningful treatments look like from the patient perspective
- Explore why regulatory agencies are increasingly interested in "Voice of the Patient" in addition to traditional efficacy and safety data
- Deep dive into data from patient-populated registries to understand why they are important complement to clinician-derived data

4.45 | 10.45 **Chair's Closing Remarks**

5.00 | 11.00 **End of Day One**

"Got chance to interact with the academic thought leaders, industrial pioneers and investors in one place."

"This is a very informative conference in next big biotechnology breakthrough!"

Shanghai Cell Therapy Group Co

DAY TWO
Thursday April 29, 2021
9AM - 5PM EST | 3PM - 11PM CEST

8.00 | 2.00 — **Online Registration & Virtual Coffee Networking**

Grab a coffee from the comfort of your own kitchen and jump into this 1:1 networking session to make new connections, exchange virtual business cards and maybe even see a friendly face or two!

8.45 | 2.45 — **Chair's Opening Remarks**

Clinical Development & Current Trials: Building a Robust Path to Clinic

Mike Murphy
Principal Investigator, MRC Mitochondrial Biology Unit
University of Cambridge

9.00 | 3.00 — **Keynote Presentation: Targeting Therapeutic Molecules to Mitochondria to Treat Ischaemia-Reperfusion (IR) Injury in Heart Attack, Stroke & Organ Transplantation**

- Discuss strategies to target small molecules to mitochondria
- Explore examples of targeting cardiac IR injury with complex I active molecules
- Discover examples of targeting mitochondrial succinate metabolism in heart attack, stroke and organ transplantation

Carole Ben-Maimon
President & Chief Executive Officer
Larimar Therapeutics

9.30 | 3.30 — **CTI-1601 as a Potential Protein Replacement Therapy under Development for Friedreich's Ataxia**

- Examine an attempt to address the unmet needs of patients with the rare disease Friedreich's Ataxia (FA)
- Take a look at the discovery and development of CTI-1601; a recombinant fusion protein to deliver frataxin
- Learn current updates on the CTI-1601 clinical program

John Geisler
Founder & Chief Scientific Officer
Mitochon Pharmaceuticals

10.00 | 4.00 — **Meaningful Pleiotropic Pharmacology for Truly Insidious Pleiotropic Diseases**

- Examine how MP101 & MP201 lowers mitochondrial calcium overload, mTOR and ROSs that drive apoptosis
- Observe how MP101 & MP201 increase cognitive factors: cAMP, CREB and BDNF that pushes repair
- Analyze how MP101 & MP201 wake up compensatory mechanisms pro-survival as an oral once-per-day brain penetrating small molecule

10.30 | 4.30 — **Virtual Speed Networking**

Grab a coffee from the comfort of your own kitchen and jump into this 1:1 networking session to make new connections, exchange virtual business cards and maybe even see a friendly face or two!

Steven Engle
Chief Executive Officer
CohBar, Inc

11.00 | 5.00 — **Showcasing Breakthrough Mitochondrial Science**

- Analyze how Cohbar are targeting a wide range of chronic and age-related diseases associated with mitochondrial dysfunction
- Examine mitochondria-based therapeutics which has benefitted from >1B years of evolution, generating entirely new approaches to diseases
- View Cohbar's pipeline: Technology platform generating portfolio of 5 programs

Sophie Bozec
SVP R&D Pharmacology & Scientific Communication
POXEL

11.30 | 5.30 — **Clinical Stage Molecules Targeting Mitochondrial Mechanisms & Mitochondrial Dysfunction for Metabolic Disorders**

- Understand mitochondrial dysfunction in metabolic diseases
- Examine how imeglimin; a new first in class, acts on mitochondrial bioenergetics as a new treatment for Type 2 diabetes
- Explore PXL065 a stabilized single stereoisomer of pioglitazone acts on a mitochondrial target to enable treatment of NASH
- Observe PXL770, a direct AMPK activator ameliorates mitochondrial dysfunction for the treatment of NASH

DAY TWO
Thursday April 29, 2021
9AM - 5PM EST | 3PM - 11PM CEST

12.00 | 6.00 **Panel Discussion: Recognize the Financial Difficulty of Developing Drugs for Targeting Mitochondria & Moving Drugs to the Next Phase**

- Explore the challenges of funding development
- Learn how drug developers can inspire and attract companies to invest in their novel development and pipeline
- Discover how can the industry come together to overcome the paucity of funding

Natalie Ohana Yivgi
Co-Founder & Chief Executive Officer
Minovia Therapeutics

Steven Engle
Chief Executive Officer
CohBar, Inc

Jake Chen
Professor of Biomedical Engineering
University of Alabama

Mehmood Khan
Chief Executive Officer
Life Biosciences

Magali Taiel
Chief Medical Officer
GenSight Biologics

Nicholas Hertz
Chief Scientific Officer
Mitokinin

12.45 | 6.45 **Networking Lunch**

Grab lunch from the comfort of your own kitchen and jump into this 1:1 networking session to make new connections, exchange virtual business cards and maybe even see a friendly face or two!

Natalie Ohana Yivgi
Co-Founder & Chief Executive Officer
Minovia Therapeutics

1.45 | 7.45 **Mitochondrial Augmentation Therapy (MAT): Harnessing the power of mitochondria for therapeutic purposes**

- Examine Mitochondrial Augmentation Therapy (MAT)
- Preclinical and clinical review of the multi-systemic effect of MAT in mitochondrial diseases
- Advance the research of MAT to address far reaching applications

Overcome Common Challenges with Clinical Trial Design

Matthew Klein
Chief Development Officer
PTC Therapeutics

2.15 | 8.15 **Lessons Learned in the Development of Therapies for Mitochondrial Disease**

- Explore important learnings from over a decade of mitochondrial disease drug development
- Discuss lessons learned including elements of clinical study design and regulatory strategy
- Examine how these conversations are applicable to all therapeutic modalities

Deep Dive into Gene Therapy & Editing when Targeting Mitochondria

Magali Taiel
Chief Medical Officer
GenSight Biologics

2.45 | 8.45 **Lumevoq Gene Therapy in Leber Hereditary Optic Neuropathy (LHON)**

- Examine LHON and its main clinical aspects
- Delve into late stage development of Lumevoq Gene Therapy
- Discuss regulatory pathways
- Outline key learnings of Lumevoq gene therapy

3.15 | 9.15 **Netwoking Break**

- Live Demo in the Virtual Exhibition Hall
- 1-1 Meetings

DAY TWO
Thursday April 29, 2021

9AM - 5PM EST | 3PM - 11PM CEST

Technology & Innovation: Accelerating High Tech Involvement in Daily Practice

3.45 | 9.45

Advances in Biophysical Approaches to Studying Drug Interactions with Mitochondrial Membranes & Membrane Proteins

Nathan Alder
Associate Professor
University of Connecticut

- Study how biological membranes and membrane protein complexes are key targets for drug developmentdespite the many experimental challenges they present
- Investigate how new advances in model membrane systems allow unprecedented experimental access to traditionally recalcitrant samples
- Examine innovations in structural and functional characterization of mitochondrial membrane proteins that are rendering new insights into drug interactions
- See how these technological advances have strong potential to help elucidate molecular mechanisms of action and assist in the design of next-generation analogs for mitochondria-targeted compounds

Douglas Wallace
Michael & Charles Barnett Endowed Chair
Pediatric Mitochondrial Medicine & Metabolic Disease
Director
Center for Mitochondrial & Epigenomic Medicine
Professor
University of Pennsylvania

4.15 | 10.15

A Mitochondrial Etiology of Common Diseases

- Examine how primary mitochondrial disease manifestations imply that common diseases may involve impaired mitochondrial function
- Evaluate how the complexity of the genetics of the common diseases is due to the distribution of mitochondrial genes across the mitochondrial and nuclear DNAs
- Explore human mitochondrial genetic variation including and how it's been shaped by ancient regional natural selection and how this variation can result in differential sensitivity to modern environmental challenges
- Discover therapies that prove beneficial for primary mitochondrial diseases and how they may be useful for common disorders

4.45 | 10.45 **Chair's Closing Remarks**

5.00 | 11.00 **End of Day Two & Summit**

"Positive, learn a lot. well organized and great speakers"

Juvena Therapeutics

An Interactive Online Experience

The digital **Mitochondria-Targeted Drug Development** summit is committed to delivering the high-quality insights and industry connections that our customers expect, in a format that is accessible from the comfort of your home or office.

We have created the virtual summit to satisfy the industry's need to share cutting-edge research, learn from your peers and engage in quality networking within a niche and highly selective audience to forge valuable collaborations.

To effectively facilitate this need to learn and connect, our custom-built virtual event platform will combine best-in-class features to deliver a seamless event experience. Accessing the platform is simple, you'll be provided with a unique link in the run up to the event that will take you directly to the online event space where you'll follow a few simple steps to set up your delegate profile and get started.

Key Features & Functionalities:

Delegate Profile
Set up personalized profiles to easily identify the name, job title & company of other attendees

Stage Area
Most presentations will be delivered in the 'Stage' area, much like the main conference room onsite

Sessions Area
Smaller groups can get together in this breakout area for panel discussions and other interactive sessions

Demo Area
Visit the virtual exhibition area to explore the solutions our specialist vendors have on offer

Chat Rooms
Connect with your peers and start conversations with individuals or all attendees in private and public chatrooms

Speed Networking
This virtual networking session will connect you with other attendees to establish new industry contacts

What You Can Expect from a Digital Event:

Live Q&As with Speakers
Ask your burning questions directly to our expert speakers in real-time, just as you would at a physical conference

Audience Discussions
Join smaller, informal group chats or video calls designed to spark crucial conversations around key challenges for the industry

2+ Hours of Networking
Facilitated and informal networking breaks will allow you to connect 1-2-1 with other attendees and kick start critical discussions

Content Available Post-Event
On conclusion of the event, presentations will be made available to attendees where possible

If you have any other questions about the platform, please **get in touch**

(+1) 617 455 4188 info@hansonwade.com
www.mitochondria-targets.com

Become a Commercial Partner

The inaugural, digital **Mitochondria-Targeted Drug Development** summit will bring together the leading experts and organizations committed to advancing aging research. We tailor bespoke packages to align with your commercial strategy, so get in touch to learn more about exclusive partnership opportunities. Establish yourself as thought leader and foster long-term partnerships with fast growing longevity pharma and biotech companies today!

Mitochondria-targeted therapy developers are actively seeking external partners that can provide solutions to the challenges they are facing when manufacturing, scaling and commercializing these therapeutics.

This is the perfect opportunity to demonstrate your technology, expertise and capacity to meet the increasing demands of this field.

Secure a virtual exhibition booth to **showcase your expertise and educate the industry on how you can support and streamline their efforts**

Maximize the 2:1 balance of live content and targeted online networking to **facilitate lead generation and build new relationships with senior level decision makers from leading pharma and biotech companies**

Secure a branding or speaking opportunity to **demonstrate your thought leadership, drive your brand exposure and differentiate yourself from competitors**

Embrace the tech to **meet your 2021 business objectives and educate key decision makers on how your expertise can help ensure Mitochondria-targeted drugs reaches its full potential and get to patients in need**

> "The conference was very useful and fulfilled all my expectations regarding what I will gain by attending"
>
> **TeneoBio**

GET INVOLVED

Flavia Alexandru
Business Development Manager
Tel: (+1) 6174554188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways To Book

www.mitochondria-targets.com/take-part/register

Tel: (+1) 617 455 4188

Email: register@hansonwade.com

1 **SAVE** valuable time and resources by learning how the leading companies in the space have optimized discovery, translational and analytical approaches to target mitochondria

2 **GAIN** first-hand insights from senior experts already navigating and overcoming challenges in advancing mitochondria-targeted therapeutics

3 **FORM** lasting connections by engaging directly with colleagues from the leading pharma and biotech companies actively researching and developing mitochondria-targeted therapeutics in a virtual environment

Secure Your Place Now

Industry Pricing	Register & Pay before Friday February 12	Standard Pricing
Conference + 2 Workshops	$2,097 **(Save $600)**	$2,697
Conference + 1 Workshop	$1,848 **(Save $500)**	$2,348
Conference Only	$1,599 **(Save $400)**	$1,999

Academic/Small Biotech Pricing**	Register & Pay before Friday February 12	Standard Pricing
Conference + 2 Workshops	$1,647 **(Save $750)**	$2,397
Conference + 1 Workshop	$1,498 **(Save $600)**	$2,098
Conference Only	$1,349 **(Save $450)**	$1,799

Vendor Pricing	Register & Pay before Friday February 12	Standard Pricing
Conference + 2 Workshops	$2,647 **(Save $650)**	$3,297
Conference + 1 Workshop	$2,348 **(Save $550)**	$2,898
Conference Only	$2,049 **(Save $450)**	$2,499

* All prices shown in USD

Please note: If you are a UK or EU-based company, you may be subject to 20% VAT in addition to the price advertised. If you qualify for a reverse charge, you will have the option to provide your VAT number and the charge will be automatically deducted at checkout.

Drug Developer refers to pharma and biotech. To register at the academic rate, you must have a valid email address associated with an academic or not-for-profit organization. Bookings are subject to organizer approval and we reserve the right to reject incorrect bookings.

** To qualify for Small Biotech rate, the company needs to be less than 3 years old or have fewer than 10 full time employees. Solution providers are excluded. All bookings at this rate are subject to organizer approval.

Team Discounts*

- **10% discount – 3 Attendees**
- **15% discount – 4 Attendees**
- **20% discount – 5 or more Attendees**

*Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com